Opportunity
CanadaBuys #WS5994329939
PHAC requirement for Oblitoxaximab injection to treat inhalation anthrax
Posted
November 17, 2026
Respond By
December 08, 2026
Identifier
WS5994329939
NAICS
325414, 424210
PHAC is seeking Oblitoxaximab injection to treat inhalation anthrax. - Government buyer: Public Services and Procurement Canada (PSPC), on behalf of the Public Health Agency of Canada (PHAC). - OEM/proposed supplier: Elusys Therapeutics, Inc. - Product: Oblitoxaximab injection, an antitoxin for inhalation anthrax; no part number or quantity is specified. - Notable requirement: The notice cites exclusive rights as the basis for the proposed contract. Other suppliers may submit evidence of their capability to meet the requirement. - Services and performance period: None specified.
Description
Public Services and Procurement Canada proposes to negotiate a contract with Elusys Therapeutics, Inc. on behalf of the Public Health Agency of Canada. The procurement is for Oblitoxaximab injection, an antitoxin used to treat inhalation anthrax. This Advance Contract Award Notice allows other suppliers to submit a statement of capabilities by the closing date; if none meet the requirements, the contracting officer may proceed with the proposed award.